Definium Therapeutics oral LSD candidate DT120 has passed a late-stage study in generalized anxiety disorder (GAD), not even two months after reporting trial success for in depression.
Definium Therapeutics said Wednesday its oral LSD candidate has passed a late-stage study in generalized anxiety disorder (GAD), not even two months after reporting trial …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Definium Therapeutics says its LSD therapy eased anxiety in late-stage trial
LSD Just Passed Its Biggest Trial Yet for Anxiety
Definium says LSD-based pill reduces anxiety in late-stage study
Definium Therapeutics Says Unprecedented Efficacy From Anxiety Study 'Raises the Bar' - Definium Therapeu
Psychedelics developer Definium scores more positive data for LSD pill
This LSD-Based Drug Just Scored Again; Stock Soars
Aquestive Prepares FDA Resubmission for Severe Allergy Treatment Following Successful Study - Aquestive T
Definium's LSD drug DT120 hit its Phase 3 MDD primary endpoint, beating analyst expectations with significant improvement in…
Definium Therapeutics said that its LSD therapy significantly helped patients with generalized anxiety disorder in the first of…
It's the second major victory this year for Definium Therapeutics and its proprietary version of LSD.
Definium's LSD-based pill significantly reduces anxiety in a late-stage study, boosting shares over 20% amid promising results.
Definium Therapeutics says positive Phase 3 trial results for DT120, shows significant and rapid symptom improvement in anxiety…
DT120, a psychedelic that activates serotonin receptors, was generally well tolerated, with mostly mild side effects occurring on…
